Alternate-day dosing of linagliptin in type 2 diabetes patients controlled on once daily dose: A case series

Linagliptin, a dipeptidyl peptidase 4 (DPP 4) inhibitor with a long terminal half life, significantly inhibits the DPP 4 enzyme at a steady state up to 48 h after the last dose. The present case series examined the hypothesis that linagliptin retains its efficacy during alternate day dosing in type...

Descripción completa

Detalles Bibliográficos
Autores principales: Baruah, Manash P., Bhuyan, Sonali B., Deka, Jumi, Bora, Jatin, Bora, Smritisikha, Barkakati, Murchana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911851/
https://www.ncbi.nlm.nih.gov/pubmed/27366728
http://dx.doi.org/10.4103/2230-8210.183468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911851/
https://www.ncbi.nlm.nih.gov/pubmed/27366728
http://dx.doi.org/10.4103/2230-8210.183468

Ejemplares similares